TELOMERASE NOBEL PRIZE More than 35 years ago, telomerase activity was discovered by Elizabeth H. Blackburn and Carol W. Greider. Today, this enzyme is a promising approach to curing some age-related diseases as well as cancer, but it took time for telomerase to be in the spotlight. The existence of an enzyme, a DNA polymerase, that could elongate the ends of chromosomes or telomeres was predicted in 1984 on the basis of telomere maintenance and net telomere elongation in both ciliates and yeast1. Some fifty years before that discovery, the work of Hermann Müller and Barbara McClintock had showed the occurrence of a special structure at chromosome ends — which Müller termed the telomere — that was essential to prevent chromosomes from fusing to each other2,3. The subsequent elucidation of the structure of the DNA molecule and the understanding of the DNA replication mechanisms posed the question on how to maintain the ends of chromosomes throughout cellular and organismal generations. James D. Watson and Alexey M. Olovnikov had envisioned that the ends of linear DNA molecules, such as chromosomes, would shorten every time a cell divides, owing to the incomplete replication of the ends by the conventional polymerases, a problem termed the end replication problem. Thus, to allow for species maintenance, an enzyme must exist that would compensate for the ever-shorter telomeres associated to cell division. Such an enzyme was predicted by Elizabeth H. Blackburn and Jack W. Szostak to elongate the 3´ ends of telomeric repeats to compensate for telomere loss associated to cell division, so that in this manner the ends of chromosomes would not wear away after a few cell divisions, generating chromosomal instability. To find such an enzyme was of potential great importance, as its telomere elongating activity or the lack thereof could explain the limited life span of normal cells, also known as the Hayflick limit4 as well as organismal aging and longevity. Such an activity
Reviews
There are no reviews yet.